NASDAQ:CDT Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free CDT Stock Alerts $3.17 +0.07 (+2.26%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share Today's Range$3.05▼$3.1750-Day Range$2.57▼$3.6852-Week Range$0.95▼$25.00Volume5,500 shsAverage Volume35,320 shsMarket Capitalization$230.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Conduit Pharmaceuticals alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Conduit Pharmaceuticals Stock (NASDAQ:CDT)Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Read More CDT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDT Stock News HeadlinesMarch 19, 2024 | finance.yahoo.comConduit Pharmaceuticals Adds Key Leadership PositionsMarch 19, 2024 | globenewswire.comConduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific OfficerApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 11, 2024 | finance.yahoo.comConduit Pharmaceuticals Opens New Laboratory in UKMarch 11, 2024 | finance.yahoo.comConduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences HubMarch 11, 2024 | globenewswire.comConduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences HubFebruary 28, 2024 | seekingalpha.comConduit Pharmaceuticals: Stellar Management Team, New Business ModelFebruary 15, 2024 | sg.finance.yahoo.comConduit Pharmaceuticals Inc. (CDT)April 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 13, 2024 | uk.finance.yahoo.comConduit Pharmaceuticals Inc. (CDTTW)January 31, 2024 | finance.yahoo.comConduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceDecember 6, 2023 | wsj.comConduit Pharmaceuticals Inc.November 2, 2023 | finance.yahoo.comConduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare ConferenceOctober 31, 2023 | msn.comKXIN and ICU among pre-market losersOctober 28, 2023 | seekingalpha.comCDT Conduit Pharmaceuticals Inc.October 24, 2023 | uk.investing.comConduit Pharmaceuticals Inc (CDT)October 11, 2023 | finance.yahoo.comConduit Pharma CEO Tapolczay on Biopharma Differentiation, PipelineOctober 11, 2023 | finance.yahoo.comConduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656See More Headlines Receive CDT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Next Earnings (Estimated)7/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CDT Previous SymbolNASDAQ:CDT CUSIPN/A CIK1896212 Webwww.conduitpharma.com Phone760-471-8536FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-3.20% Debt Debt-to-Equity RatioN/A Current Ratio3.18 Quick Ratio3.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-317.00Miscellaneous Outstanding Shares72,810,000Free Float55,710,000Market Cap$230.81 million OptionableNot Optionable Beta2.47 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. David Joszef Tapolczay (Age 65)CEO & Director Comp: $419.8kMr. Adam Sragovicz (Age 54)Chief Financial Officer Comp: $116.67kDr. Joanne M. Holland (Age 49)Chief Scientific Officer Key CompetitorsNektar TherapeuticsNASDAQ:NKTRuniQureNASDAQ:QUREAldeyra TherapeuticsNASDAQ:ALDXOvid TherapeuticsNASDAQ:OVID23andMeNASDAQ:MEView All Competitors CDT Stock Analysis - Frequently Asked Questions How have CDT shares performed in 2024? Conduit Pharmaceuticals' stock was trading at $4.55 at the beginning of 2024. Since then, CDT stock has decreased by 30.3% and is now trading at $3.17. View the best growth stocks for 2024 here. Are investors shorting Conduit Pharmaceuticals? Conduit Pharmaceuticals saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 40,900 shares, a drop of 25.8% from the March 31st total of 55,100 shares. Based on an average trading volume of 33,100 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.4% of the company's shares are short sold. View Conduit Pharmaceuticals' Short Interest. When is Conduit Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 16th 2024. View our CDT earnings forecast. How do I buy shares of Conduit Pharmaceuticals? Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDT) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressGreat Crypto BullWeiss RatingsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
